



Fig. S1. Gating strategy, MAIT cell abundance and alteration of soluble factors in COVID-19 patients. (A) Gating strategy used for the identification of each T cells subsets. **(B)** Graphs (median ± IQR) showing the absolute counts of MAIT cell subsets in healthy control (HD; n=14), acute moderate (AM; n=9) and acute severe (AS; n=15) COVID-19 patients. Non-parametric Kruskal-Wallis test and Dunn's post-hoc test were used to detect significant differences between groups. *p<0.05, **p<0.01, ***p<0.001, ****p<0.001. **(C)** Left: UMAP plot displaying T cell clusters identified based on gene expression levels in bronchoalveolar lavages (n=4 healthy donors and n=9 COVID-19 patients). Middle: UMAP plots showing expression of the canonical transcripts TRAV1-2, KLRB1, SLC4A10, IL7R used for MAIT cell identification. Right: graphs of MAIT cell frequency in bronchoalveolar lavages from healthy donors (HD) and COVID-19 patients. **(D)** Box plots comparing IL17C, CXCL11, CCL28 and CCL20 serum levels between Healthy donors (HD, n=14) and COVID-19 patients (n=24). Non-parametric Mann-Whitney test was used to detect significant differences between groups. Horizontal bars indicate medians. Each dot represents one donor. Non-parametric Mann-Whitney U test was used to test for significant differences between groups.



Fig. S2. Phenotypic alterations of peripheral blood MAIT cells and other T cell subsets in COVID-19 patients. (A) Top: Illustrative concatenated flow cytometry plots showing the percentage of expression of the indicated phenotypic markers on MAIT cells by patient group. Bottom: graphs (median \pm IQR) showing the percentage of expression of the indicated markers on MAIT cells in healthy control (HD; n=14), acute moderate (AM; n=9) and acute severe (AS; n=14) COVID-19 patients. Nonparametric Kruskal-Wallis test was used to detect significant differences between groups. *p<0.05, **p< 0.01, ***p<0.001, ****p<0.001. (B) Heatmaps displaying the percentage of expression of the indicated markers in CD8, CD4 and DN MAIT cells subsets. (C) Heatmaps summarizing the percentage of expression of the indicated markers in the identified T cell subsets. *p<0.05, **p<0.001.



Fig. S3. Transcriptional profiling of the MAIT cell compartment in the upper respiratory tract. Left: violin plots of the expression levels of functional transcripts in the thirteen T cell clusters identified in nasopharyngeal swabs (n=5 healthy donors, and n=19 COVID-19 patients). Cluster 4 was identified as the MAIT cell compartment, highlighted with black rectangle. Right: heatmap highlighting the distribution of expression of the indicated transcripts on the UMAP projection.



Fig. S4. Associations and correlations of MAIT cell count and phenotype with clinical parameters, cytokine and chemokine levels in serum. (A) Heatmap displaying rank-biserial correlations between MAIT cell count, phenotype and clinical parameters in COVID-19 patients. Color indicates effect size and stars indicate Mann-Whitney p-values. (B) Heatmap displaying pairwise spearman correlations between MAIT cell count, phenotype and cytokine serum levels in COVID-19 patients. (C) Heatmap displaying pairwise spearman correlations between MAIT cell count, phenotype and cytokine serum levels in COVID-19 patients. (C) Heatmap displaying pairwise spearman correlations between MAIT cell count, phenotype and chemokine serum levels in COVID-19 patients. (D) Heatmap displaying pairwise spearman correlations between MAIT cell count, phenotype and clinical parameters in COVID-19 patients. (B, C, D) Color indicates the strength of the correlation. *p<0.05, **p<0.01, ***p<0.001.





Table S1. Demographic and clinical characteristics of the acute COVID-19 Atlas cohort, healthy donors, and convalescent patients.

	Healthy donors	Acute d Atlas d	lisease cohort	Conva	lescent cohort
		Moderate	Severe	Mild	Moderate/Severe
n	14	9	15	23	22
Age group (median in years)	n/d	56	57	51	56
10-29	0%	11%	0%	0%	0%
30-49	21%	22%	27%	30%	36%
50-59	64%	33%	33%	48%	27%
60-69	14%	22%	27%	22%	36%
70-79	0%	11%	13%	0%	0%
Sex (male/female)	71%/29%	67%/33%	80%/20%	48%/52%	82%/18%
BMI	n/d	28.5	29.5	n/d	n/d
Smoking	n/d				
No			53%	52%	77%
Past			27%	22%	9%
Yes			13%	4%	9%
n/d		100%	7%	26%	5%
Comorbidities	n/d				
Hypertension		22%	27%	9%	41%
Diabetes		11%	27%	9%	36%
Cardiovascular disease		22%	13%	0%	18%
Symptoms at admission					
Cough	n/d	89%	80%	n/d	n/d
Body ache	n/d	33%	53%	n/d	n/d
GI related	n/d	11%	20%	n/d	n/d
Fever	n/d	100%	100%	n/d	n/d
Dyspnea	n/d	100%	100%	n/d	n/d
Positive viremia at sampling	n/d	44%	47%	n/d	n/d
Positive blood culture +/- 5 days from sampling	n/d	0%	20%	n/d	n/d
Positive lower respiratory culture +/- 5 days from sampling	n/d	0%	40%	n/d	n/d
SOFA total at sampling	n/d			n/d	n/d
0		11%	0%		
1		78%	0%		
2		11%	7%		
3		0%	27%		
4		0%	13%		
6		0%	33%		
7		0%	7%		

9		0%	7%		
12		0%	7%		
NIH Ordinal Scale at sampling	n/d			n/d	n/d
4		44%	0%		
5		78%	27%		
7		0%	73%		
SOFA-resp at sampling	n/d			n/d	n/d
0		22%	0%		
1		78%	0%		
2		0%	7%		
3		0%	67%		
4		0%	27%		
Maximum oxygen treatment	n/d	78%	100%	0%	45%
Low flow <15L/min		67%	20%	n/d	n/d
High flow		11%	7%	n/d	n/d
Ventilator		0%	67%	n/d	n/d
ECMO		0%	7%	n/d	n/d
Steroids prior to sampling	n/d	22%	73%	n/d	n/d
Antibiotics prior to sampling	n/d	33%	73%	n/d	n/d
COVID-19 specific therapy	n/d	0%	13%	0%	18%
CMV IgG	71%	78%	93%	n/d	n/d
SARS-CoV2 IgG at sampling	0%	11%	80%	n/d	n/d
Outcome (deceased)	n/d	0%	27%	n/d	n/d

COVID-19 specific therapies here include antiviral treatment (Remdesivir) or cytokine blockade (Anakinra). BMI: body mass index, GI: Gastrointestinal, CMV: cytomegalovirus, ECMO: extracorporeal membrane oxygenation, n/d: non-determined.

	Acute disease Biobank cohort	
	Alive	Deceased
n	7	7
Age group (median in years)	52	58
10-29	0%	0%
30-49	14%	0%
50-59	57%	57%
60-69	29%	43%
70-79	0%	0%
Genre (male/female)	86%/14%	86%/14%
BMI	28.4	28
Smoking	n/d	n/d
Comorbidities		
Hypertension	57%	29%
Diabetes	0%	0%
Cardiovascular disease	0%	0%
Symptoms at admission	n/d	n/d
Positive viremia at sampling	n/d	n/d
Positive blood culture +/- 5 days from sampling	71%	71%
Positive lower respir culture +/- 5 days from sampling	14%	0%
NIH Ordinal Scale at sampling		
4	0%	0%
5	29%	0%
6	14%	0%
7	57%	100%
SOFA-respir at sampling	n/d	n/d
Maximum oxygen treatment		
Low flow <15L/min	29%	0%
High flow	0%	0%
Ventilator	71%	100%
ECMO	0%	0%
Steroids prior to sampling	57%	57%
Antibiotics prior to sampling	n/d	n/d
COVID-19 specific therapy	29%	14%
CMV IgG	n/d	n/d
SARS-CoV2 IgG at sampling	n/d	n/d
Outcome (deceased)	0%	100%

Table S2. Demographic and clinical characteristics of the COVID-19 Biobank cohort patients.

COVID-19 specific therapies here include antiviral treatment cytokine blockade (Anakinra, Tocilizumab). BMI: body mass index, GI: Gastrointestinal, CMV: cytomegalovirus, ECMO: extracorporeal membrane oxygenation, n/d: non-determined.

	Atlas	Biobank	
	n=24	n=14	p-value
Time in hospital	17 [10.5-24]	34.5 [26.8-38.8]	0.016
Days symtom debut to			
sampling	14 [11.8-17]	25 [21-29]	<0.001
NIH Ordinal Scale at sampling	5 [5-7]	7 [7-7]	0.029
Age	56.5 [47.2-63.8]	56.5 [52-62.8]	0.844
BMI	29 [27-34]	28.25 [26.6-31.8]	0.381
Highest CRP ± 24h	123 [99.5-271.5]	91 [46.2-134.2]	0.029
Highest neutrophils ± 24h	8.35 [5.1-11]	8.9 [7.2-11.1]	0.496
Lowest lymphocytes ± 24h	0.85 [0.5-1.3]	0.75 [0.5-1.2]	0.867
Highest ferritin ± 24h	1480 [546-1944.5]	1080 [599-3686]	0.742
Higest D-dimer ± 24h	1.3 [0.7-2.8]	4.85 [1.1-10.2]	0.022
Highest LD	8.85 [5.7-11.5]	7.3 [6.1-8.6]	0.356
Highest creatinine ± 24h	71.5 [55-86]	78.5 [56.2-134.8]	0.596
Highest bilirubin ± 24h	8 [6-9.2]	10.5 [7-16.8]	0.094
Lowest platelets ± 24h	324 [230-424]	290.5 [247-380.2]	0.778
Highest IL-6 ± 5d	94.5 [61.2-273]	92 [37.2-222]	0.626

Table S3. Demographic and clinical data comparison between the acute COVID-19 Atlas cohort and the Biobank cohort.

Values are median [Q1-Q3]. p-values were calculated using the unpaired Mann-Whitney test. The time window from measure to sampling is indicated by \pm . BMI: body mass index, CRP: c-reactive protein, LD: lactate dehydrogenase.